Clinical trials: Non Alcoholic Fatty Liver
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
De Novo Lipogenesis in Severity of NAFLD
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- NCT03683589
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Missouri-Columbia
Type 2 Diabetes, NAFLD
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although…
- Conditions
- Type 2 Diabetes, NAFLD, Obesity, Dyslipoproteinaemia
- Trial name
- DiNA-D (NCT02459496)
- Testing
- dietary consulting and advise
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
Fatty Liver Disease
The Role of Sugars in Fat Accumulation in the Liver
This interventional study has 2 parts. In the part A of the project, we will determine how the acute changes in hepatic fat content (HFC) after high-fat load (150 g of fat) are affected by co-administration with three doses of…
- Trial name
- FROGLOSA (NCT06751862)
- Testing
- 150g of fat with glucose, 150g of fat with fructose, 150g of fat with sucrose
- Where
- Czechia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute for Clinical and Experimental Medicine
Sensitivity to Thyroid Hormones, Metabolic Parameters
Effects of Intermittent Fasting on Fatty Liver Disease
Eighty subjects with FLD were recruited from the endocrinology clinic at Beijing Chao-yang Hospital. All of the following inclusion criteria needed to be met: hepatic fat content (HFC) were upper 5.0% evaluated by upper abdominal…
- Conditions
- Sensitivity to Thyroid Hormones, Metabolic Parameters, in Patients With FLD
- Trial name
- NCT04795973
- Testing
- 5:2 intermittent fasting
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Chao Yang Hospital
Non-Alcoholic Fatty Liver Disease, Obesity
Lifestyle Interventions for the Treatment of Non-alcoholic Fatty Liver Disease in Overweight and Obese Adults
Lifestyle intervention is the most important management of non-alcoholic fatty liver diseases (NAFLD) patients. Weight reductions of 5-10% can improve non-alcoholic steatosis and fibrosis.
- Trial name
- NCT03972631
- Testing
- Lifestyle education, Intensive lifestyle intervention, Hypocaloric low-carbohydrate diet plan
- Volunteers
- 292 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States.
- Trial name
- NCT04031729
- Testing
- Aspirin 81 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
NAFLD
Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans
High levels of fatty substances in the blood increase the risk of developing heart disease. Investigators know a lot about one of these fatty substances, cholesterol.
- Trial name
- NCT01936779
- Testing
- Dietary supplement: fatty acid
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Non-Alcoholic Fatty Liver Disease, Obesity
Alternate Day Fasting, Exercise, and NAFLD
Approximately 65% of obese individuals have non-alcoholic fatty liver disease (NAFLD), and this condition is strongly related to the development of insulin resistance and diabetes.
- Trial name
- NCT04004403
- Testing
- Alternate day fasting, Exercise
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Non-alcoholic Fatty Liver Disease (NAFLD)
Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
This study will evaluate the association of non-alcoholic fatty liver disease and diabetes mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive the following examination: Transient…
- Trial name
- NCT01997424
- Testing
- Controlled Attenuation Parameter (CAP), Echosens, Paris, France, FibroScan, Echosens, Paris, France
- Where
- Germany
- Volunteers
- 340 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
NASH - Nonalcoholic Steatohepatitis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
- Trial name
- NCT04897594
- Testing
- TERN-201
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Nonalcoholic Fatty Liver Disease
The University of Michigan Wellness for Liver Health Study
The goal of this proposal is to pilot test our existing very-low carbohydrate diet intervention, adapted for adults with Non-alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05010070
- Testing
- diet and lifestyle program
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
NAFLD, Steatosis of Liver
Response of NAFLD Patients to Mediterranean Diet
The effects of Mediterranean Diet (MedDiet) on clinical, biochemical and inflammatory profile in NAFLD patients with simple steatosis.
- Trial name
- NCT03203486
- Testing
- Mediterranean Diet
- Volunteers
- 44 people
- Sponsor
- Harokopio University
Nonalcoholic Fatty Liver Disease
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.
- Trial name
- NCT02029586
- Testing
- MB12066 200mg
- Where
- 10 sites in South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Obesity
Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.
It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients within this group have a more serious liver…
- Trial name
- NCT00280527
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Northwestern University
NASH - Nonalcoholic Steatohepatitis
Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat
Evaluate the relationship between the severity of fatty liver in NAFLD assessed by ultrasonography and CT and the visceral fat area measured by CT
- Trial name
- NCT04240145
- Testing
- MSCT Abdomen
- Volunteers
- 35 people
- Sponsor
- Gehad Abd Elaziz Mhmoud Ahmad
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
MLCT Oil for Fatty Liver - PASS Trial
The main objective of this randomised pilot study is to explore the relative efficacy of dietary MLCT oil versus LCT oil (corn oil) in augmenting therapy of overweight and obese NAFLD patients with at least a 1-stage reversal…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, NAFLD
- Trial name
- PASS (NCT05217745)
- Testing
- MLCT Oil, LCT Oil (Corn Oil)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Non-Alcoholic Steatohepatitis (NASH)
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
The primary objective of this study is to characterize the safety, tolerability and dose-limiting toxicities (DLTs) for GR-MD-02 when administered intravenously to subjects with biopsy-proven NASH with advanced liver fibrosis.
- Trial name
- NCT01899859
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Galectin Therapeutics Inc.
NAFLD, Hiv
Lifestyle Modification Programme for HIV-infected Individuals With Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and will likely become the predominant cause of chronic liver disease in HIV-infected individuals.
- Trial name
- NCT03913351
- Testing
- Lifestyle modification
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
Non-alcoholic Steatohepatitis
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by…
- Trial name
- NCT04722653
- Testing
- NNC0194-0499
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Fatty Liver, NAFLD
Effect of CoQ10 on the Outcome of MAFLD Patients
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors.
- Trial name
- NCT05984745
- Testing
- Coenzyme Q10 Forte® capsules
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.